Hitachi, Ltd. and Centre Leon Berard (CLB), a leading French Comprehensive Cancer Center in Lyon-France, announced that they have entered into an agreement to jointly promote research and development aimed at improving the efficiency of diagnosis and treatment of cancer and established a new research laboratory called Hitachi Lyon Lab on the CLB site, starting November 5th. In this collaboration, Hitachi and CLB will conduct research and development of novel technologies to detect and diagnose cancers exploiting medical images such as CT/MRI using artificial intelligence (AI) and to predict response to radiation therapy using tumor genomic and transcriptomic data. Hitachi provides solutions that improve the quality and efficiency of medical care, from diagnostic/clinical fields such as diagnostic imaging equipment and particle therapy systems to informatics fields such as IT and AI. In addition, Hitachi has been contributing to maintaining and improving people's quality of life by delivering particle therapy systems to a number of world-renowned hospitals, where more than 60,000 people have been treated with Hitachi's systems so far. Hitachi and CLB will conduct joint research at Hitachi Lyon Lab to improve the efficiency of diagnosis and treatment of cancer, by combining CLB's clinical expertise and patient data related to cancer treatment with Hitachi's know-how in diagnostic imaging and IT/AI. Specifically, they will jointly develop diagnostic imaging technologies to detect potential cancer sites and assist radiologists' diagnosis from image data such as CT and MRI using AI. Identification of biomarkers exploiting genomic data in the context of resistance will allow to predict responses and prognoses upon radiation treatment. Hitachi will continue to accelerate global RD with advanced medical institutions and universities in the healthcare field, and will work with partners in joint research to create new value and contribute to improving the quality and efficiency of care.